The 16th CPhI China was held in Shanghai New International Expo Center from June 21 to 23, 2016. PharmaBlock Sciences (Nanjing), Inc., along with its subsidiaries—BTC Pharmaceuticals Co. Ltd. and Shandong Diai Biotechnology Co. Ltd., jointly participated in the exposition.
Over the past years, PharmaBlock has gained recognition for its outstanding capability in the design, synthesis and supply of lab scale building blocks. Continuing on this success, the company established BTC Pharmaceuticals Co. Ltd. as its pilot plant in 2015, and acquired Shandong Diai Biotechnology Co., Ltd. as its manufacturing site in 2016. “The reason PharmaBlock keeps developing manufacturing capability of key intermediates and APIs is that we are committed to a more comprehensive and long-term service to valued customers by satisfying the different chemistry synthesis needs throughout the pharmaceutical R&D.” Dr. Minmin Yang, Chairman of PharmaBlock explained.
Dr. Haijun Dong, CEO of PharmaBlock was interviewed during the CPhI China and said, “We have partnered with many top pharmaceutical companies on projects ranging from lab scale to kilogram and even hundreds of kilogram scale. Our seamless technology transfer ensures the smooth running as clients’ programs advance from preclinical to commercial.”
PharmaBlock was officially listed on the New Third Board in China this June and is planning to file IPO for the GEM exchanges approximately at the end of 2016.